CliffBio
small molecule

METRONIDAZOLE

METRONIDAZOLE

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameMETRONIDAZOLE
Active ingredientMETRONIDAZOLE
Strength0.75%
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalJuly 2006
Marketing statusRX

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.